N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats

Neuropharmacology

Volumn 58, Issue 1, 2010, Pages 304-313

  Xi, Zheng Xiong ^a   Kiyatkin, Michael ^a   Li, Xia ^a   Peng, Xiao Qing ^a   Wiggins, Armina ^a   Spiller, Krista ^a   Li, Jie ^a   Gardner, Eliot L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

2 PMPA; Brain reward; Cocaine; DA; LY341495; mGlu2; mGlu3; NAAG; Self administration

Indexed keywords

2 (PHOSPHONOMETHYL)PENTANEDIOIC ACID; COCAINE; DOPAMINE; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; N ACETYLASPARTYLGLUTAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEPTH STIMULATION; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; IN VIVO STUDY; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; REINFORCEMENT; REWARD; SYSTEMIC THERAPY;

ANIMALS; BEHAVIOR, ADDICTIVE; BRAIN; COCAINE; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; INJECTIONS, INTRAVENOUS; MALE; MICRODIALYSIS; NEUROPROTECTIVE AGENTS; ORGANOPHOSPHORUS COMPOUNDS; RATS; RATS, LONG-EVANS; REINFORCEMENT SCHEDULE; REWARD; SELF ADMINISTRATION;

EID: 71549170805     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.06.016     Document Type: Article

References (67)

1. Adewale A.S., Platt D.M., and Spealman R.D. Pharmacological stimulation of group II metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys. J. Pharmacol. Exp. Ther. 318 (2006) 922-931
2. Aragona B.J., Cleaveland N.A., Stuber G.D., Day J.J., Carelli R.M., and Wightman R.M. Preferential enhancement of dopamine transmission within the nucleus accumbens shell by cocaine is attributable to a direct increase in phasic dopamine release events. J. Neurosci. 28 (2008) 8821-8831
3. Arnold J.M., and Roberts D.C.S. A critique of fixed ratio and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol. Biochem. Behav. 57 (1997) 441-447
4. Bäckström P., and Hyytiä P. Suppression of alcohol self-administration and cue-induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)-3,4-DCPG. Eur. J. Pharmacol. 528 (2005) 110-118
5. Baptista M.A., Martin-Fardon R., and Weiss F. Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer. J. Neurosci. 24 (2004) 4723-4727
6. Carboni E., Spielewoy C., Vacca C., Nosten-Bertrand M., Giros B., and Di Chiara G. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J. Neurosci. 21 RC141 (2001) 1-4
7. Cartmell J., Adam G., Chaboz S., Henningsen R., Kemp J.A., Klingelschmidt A., Metzler V., Monsma F., Schaffhauser H., Wichmann J., and Mutel V. Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes. Br. J. Pharmacol. 123 (1998) 497-504
8. Cartmell J., Monn J.A., and Schoepp D.D. Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268. Naunyn Schmiedebergs Arch. Pharmacol. 361 (2000) 39-46
9. Chopra M., Yao Y., Blake T.J., Hampson D.R., and Johnson E.C. The neuroactive peptide N-acetylaspartylglutamate (NAAG) is not an agonist at the mGluR3 subtype of metabotropic glutamate receptor. J. Pharmacol. Exp. Ther. 330 (2009) 212-219
10. Collado I., Pedregal C., Mazón A., Espinosa J.F., Blanco-Urgoiti J., Schoepp D.D., Wright R.A., Johnson B.G., and Kingston A.E. (2 S,1' S,2' S,3' R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. J. Med. Chem. 45 (2002) 3619-3629
11. Costantino H.R., Illum L., Brandt G., Johnson P.H., and Quay S.C. Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm. 337 (2007) 1-24
12. Fell M.J., Svensson K.A., Johnson B.G., and Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1 R,4 S,5 S,6 S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 326 (2008) 209-217
13. Fiorino D.F., Coury A., Fibiger H.C., and Phillips A.G. Electrical stimulation of reward sites in the ventral tegmental area increases dopamine transmission in the nucleus accumbens of the rat. Behav. Brain Res. 55 (1993) 131-141
14. Fricker A.C., Selina Mok M.H., de la Flor R., Shah A.J., Woolley M., Dawson L.A., and Kew J.N. Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology 56 (2009) 1060-1067
15. Fuhrman S., Palkovits M., Cassidy M., and Neale J.H. The regional distribution of N-acetylaspartylglutamate (NAAG) and peptidase activity against NAAG in the rat nervous system. J. Neurochem. 62 (1994) 275-281
16. Galici R., Echemendia N.G., Rodriguez A.L., and Conn P.J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 315 (2005) 1181-1187
17. Giros B., Jaber M., Jones S.R., Wightman R.M., and Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379 (1996) 606-612
18. Hernández G., and Shizgal P. Dynamic changes in dopamine tone during self-stimulation of the ventral tegmental area in rats. Behav. Brain Res. 198 (2009) 91-97
19. Hu G., Duffy P., Swanson C., Ghasemzadeh M.B., and Kalivas P.W. The regulation of dopamine transmission by metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 289 (1999) 412-416
20. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov. Today 7 (2002) 1184-1189
21. Illum L. Nasal drug delivery-possibilities, problems and solutions. J. Control Release 87 (2003) 187-198
22. Jackson P.F., Cole D.C., Slusher B.S., Stetz S.L., Ross L.E., Donzanti B.A., and Trainor D.A. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated-[rId45]-linked acidic dipeptidase. J. Med. Chem. 39 (1996) 619-622
23. Johnson M.P., Baez M., Jagdmann Jr. G.E., Britton T.C., Large T.H., Callagaro D.O., Tizzano J.P., Monn J.A., and Schoepp D.D. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J. Med. Chem. 46 (2003) 3189-3192
24. Kalivas P.W. Glutamate systems in cocaine addiction. Curr. Opin. Pharmacol. 4 (2004) 23-29
25. Kingston A.E., Ornstein P.L., Wright R.A., Johnson B.G., Mayne N.G., Burnett J.P., Belagaje R., Wu S., and Schoepp D.D. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 37 (1998) 1-12
26. Kruk Z.L., Cheeta S., Milla J., Muscat R., Williams J.E., and Willner P. Real time measurement of stimulated dopamine release in the conscious rat using fast cyclic voltammetry: dopamine release is not observed during intracranial self stimulation. J. Neurosci. Methods 79 (1998) 9-19
27. Lea IV P.M., Wroblewska B., Sarvey J.M., and Neale J.H. β-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J. Neurophysiol. 85 (2001) 1097-1106
28. Liechti M.E., Lhuillier L., Kaupmann K., and Markou A. Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J. Neurosci. 27 (2007) 9077-9085
29. Liechti M.E., and Markou A. Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats. Biochem. Pharmacol. 74 (2007) 1299-1307
30. Linden A.-M., Baez M., Bergeron M., and Schoepp D.D. Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus. Neuropharmacology 51 (2006) 213-228
31. Lu L., Uejima J.L., Gray S.M., Bossert J.M., and Shaham Y. Systemic and central amygdala injections of the mGluR2/3 agonist LY379268 attenuate the expression of incubation of cocaine craving. Biol. Psychiatry 61 (2007) 591-598
32. Miliaressis E., Emond C., and Merali Z. Re-evaluation of the role of dopamine in intracranial self-stimulation using in vivo microdialysis. Behav. Brain Res. 46 (1991) 43-48
33. Morgan D., Liu Y., and Roberts D.C.S. Rapid and persistent sensitization to the reinforcing effects of cocaine. Neuropsychopharmacology 31 (2006) 121-128
34. Morgan D., and Roberts D.C.S. Sensitization to the reinforcing effects of cocaine following binge-abstinent self-administration. Neurosci. Biobehav. Rev. 27 (2004) 803-812
35. Morishima Y., Miyakawa T., Furuyashiki T., Tanaka Y., Mizuma H., and Nakanishi S. Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4170-4175
36. Nagel J., Belozertseva I., Greco S., Kashkin V., Malyshkin A., Jirgensons A., Shekunova E., Eilbacher B., Bespalov A., and Danysz W. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. Neuropharmacology 51 (2006) 1163-1171
37. Nakahara D., Fuchikami K., Ozaki N., Iwasaki T., and Nagatsu T. Differential effect of self-stimulation on dopamine release and metabolism in the rat medial frontal cortex, nucleus accumbens and striatum studied by in vivo microdialysis. Brain Res. 574 (1992) 164-170
38. Neale J.H., Bzdega T., and Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J. Neurochem. 75 (2000) 443-452
39. Neale J.H., Olszewski R.T., Gehl L.M., Wroblewska B., and Bzdega T. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol. Sci. 26 (2005) 477-484
40. O'Brien C.P., and Gardner E.L. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol. Ther. 108 (2005) 18-58
41. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. fourth ed. (1998), Academic Press, San Diego, CA
42. Peters J., and Kalivas P.W. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology 186 (2006) 143-149
43. Phillips A.G., Coury A., Fiorino D., LePiane F.G., Brown E., and Fibiger H.C. Self-stimulation of the ventral tegmental area enhances dopamine release in the nucleus accumbens: a microdialysis study. Ann. N. Y. Acad. Sci. 654 (1992) 199-206
44. Pöschel B., Wroblewska B., Heinemann U., and Manahan-Vaughan D. The metabotropic glutamate receptor mGluR3 is critically required for hippocampal long-term depression and modulates long-term potentiation in the dentate gyrus of freely moving rats. Cereb. Cortex 15 (2005) 1414-1423
45. Richardson N.R., and Roberts D.C.S. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J. Neurosci. Methods 66 (1996) 1-11
46. Serval V., Barbeito L., Pittaluga A., Cheramy A., Lavielle S., and Glowinski J. Competitive inhibition of N-acetylated-α-linked acidic dipeptidase activity by N-acetyl-l-aspartyl-β-linked l-glutamate. J. Neurochem. 55 (1990) 39-46
47. Shippenberg T.S., Rea W., and Slusher B.S. Modulation of behavioral sensitization to cocaine by NAALADase inhibition. Synapse 38 (2000) 161-166
48. Slusher B.S., Thomas A., Paul M., Schad C.A., and Ashby Jr. C.R. Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-acetylated-α-linked-acidic dipeptidase (NAALADASE). Synapse 41 (2001) 22-28
49. Slusher B.S., Vornov J.J., Thomas A.G., Hurn P.D., Harukuni I., Bhardwaj A., Traystman R.J., Robinson M.B., Britton P., Lu X.C., Tortella F.C., Wozniak K.M., Yudkoff M., Potter B.M., and Jackson P.F. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 5 (1999) 1396-1402
50. 3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology 196 (2008) 533-542
51. Spinelli S., Ballard T., Gatti-McArthur S., Richards G.J., Kapps M., Woltering T., Wichmann J., Stadler H., Feldon J., and Pryce C.R. Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys. Psychopharmacology 179 (2005) 292-302
52. Stewart J. Psychological and neural mechanisms of relapse. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363 (2008) 3147-3158
53. Tsukamoto T., Wozniak K.M., and Slusher B.S. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov. Today 12 (2007) 767-776
54. Uejima J.L., Bossert J.M., Poles G.C., and Lu L. Systemic and central amygdala injections of the mGluR2/3 agonist LY379268 attenuate the expression of incubation of sucrose craving in rats. Behav. Brain Res. 181 (2007) 292-296
55. Venton B.J., Seipel A.T., Phillips P.E., Wetsel W.C., Gitler D., Greengard P., Augustine G.J., and Wightman R.M. Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J. Neurosci. 26 (2006) 3206-3209
56. Westbrook G.L., Mayer M.L., Namboodiri M.A., and Neale J.H. High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture. J. Neurosci. 6 (1986) 3385-3392
57. Wise R.A. Role of brain dopamine in food reward and reinforcement. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361 (2006) 1149-1158
58. Wise R.A., and Gardner E.L. Animal models of addiction. In: Charney D.S., and Nestler E.J. (Eds). Neurobiology of Mental Illness. second ed. (2004), Oxford Univ. Press, London 683-697
59. Witkin J.M., Gasior M., Schad C., Zapata A., Shippenberg T., Hartman T., and Slusher B.S. NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology 43 (2002) 348-356
60. Woolley M.L., Pemberton D.J., Bate S., Corti C., and Jones D.N.C. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology 196 (2008) 431-440
61. Wroblewska B., Wegorzewska I.N., Bzdega T., Olszewski R.T., and Neale J.H. Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes. J. Neurochem. 96 (2006) 1071-1077
62. Wroblewska B., Wroblewski J.T., Pshenichkin S., Surin A., Sullivan S.E., and Neale J.H. NAAG selectively activates mGluR3 receptors in transfected cells. J. Neurochem. 69 (1997) 174-181
63. Xi Z.-X., Baker D.A., Shen H., Carson D.S., and Kalivas P.W. Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J. Pharmacol. Exp. Ther. 300 (2002) 162-171
64. Xi Z.-X., Ramamoorthy S., Baker D.A., Shen H., Samuvel D.J., and Kalivas P.W. Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. J. Pharmacol. Exp. Ther. 303 (2002) 608-615
65. 3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31 (2006) 1393-1405
66. Xi Z.X., Yang Z., Li S.J., Li X., Dillon C., Peng X.Q., Spiller K., and Gardner E.L. Levo-tetrahydropalmatine inhibits cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. Neuropharmacology. 53 (2007) 771-782
67. Yourick D.L., Koenig M.L., Durden A.V., and Long J.B. N-acetylaspartylglutamate and β-NAAG protect against injury induced by NMDA and hypoxia in primary spinal cord cultures. Brain Res. 991 (2003) 56-64